Status:
COMPLETED
Role of Microparticles in Covid-19 Infection
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
Among the distinctive features of Covid-19, numerous reports have stressed the importance of vascular damages associated with coagulopathy onset. Microparticles (MPs) shed by apoptotic/stimulated cell...
Detailed Description
Circulating MPs will be isolated from Covid-19 patients with lupus anticoagulant, from coronary artery diseases patients and from healthy volunteers without cardiovascular risk factors. Quantification...
Eligibility Criteria
Inclusion
- COVID-19 patients: age \> 18 yr
- SARS-COV-2 infection within 12 months and positive lupus anticoagulant
- Patients with cardiovascular risk factors: at least among
- Hypertension, Dyslipidemia, Diabetes mellitus, obesity, smoker, Healthy volunteers
Exclusion
- Significant comorbidities (active cancer, auto-immune diseases…)
Key Trial Info
Start Date :
July 2 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 4 2021
Estimated Enrollment :
189 Patients enrolled
Trial Details
Trial ID
NCT04448743
Start Date
July 2 2020
End Date
October 4 2021
Last Update
June 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Olivier MOREL
Strasbourg, France, 67000